BioSpace News Archive

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, is to provide study updates in two poster presentations from its Phase II clinical development programme with bemcentinib, a first-in-class highly selective oral AXL inhibitor, at the European Society for Medical Oncology 2019 Congress, in Barcelona.

Pfizer Inc. announced positive top-line results from a second Phase 3 pivotal study evaluating the efficacy and safety of its investigational oral Janus kinase 1 inhibitor, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis.

Tmunity Therapeutics, Inc. announced that Christina Coughlin, MD, PhD, Executive Vice President and Chief Medical Officer, and members of the management team plan to participate at the Cantor Fitzgerald 2019 Global Healthcare Conference in New York City on October 3, 2019.

Phathom Pharmaceuticals, Inc. announced that Terrie Curran will be appointed Chief Executive Officer effective upon the closing of the acquisition of Celgene Corporation by Bristol-Myers Squibb Company.

Currax Pharmaceuticals LLC, a specialty biopharmaceutical company with both Branded and generic business units, announced the acquisition of Nalpropion Pharmaceuticals.

Building on Success of its True3D Mixed Reality Software Platform, EchoPixel’s Transformative Intraoperative Imaging Tools Enable the OR of the Future

World Heart Day is the biggest awareness-raising platform for CVD and this year we are using it to shine a spotlight on heart health inequities.

Data presented at ESMO support the planned submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pemigatinib before the end of 2019

Sunovion Pharmaceuticals Inc. and PsychoGenics Inc. announced the initiation of the DIAMOND (Developing Innovative Approaches for Mental Disorders) Phase 3 studies for SEP-363856, a novel agent for the treatment of adults and adolescents with schizophrenia.

Xstrahl Medical, global leader in superficial radiotherapy devices to treat non-melanoma skin cancer and dermatological conditions, is featuring its RADiant treatment system at the Fall Texas Dermatology meeting in San Antonio, Texas, from September 27th-29th.